Skip to main content

Advertisement

Table 1 Body weight and glycaemic, insulinaemic and lipidic profile in the rats under study at the initial and final times

From: Sitagliptin prevents aggravation of endocrine and exocrine pancreatic damage in the Zucker Diabetic Fatty rat - focus on amelioration of metabolic profile and tissue cytoprotective properties

Time Initial time (20 wks old rats) Final time (26 wks old rats)
Groups Control Diabetic Control Diabetic
Parameters Vehicle (n = 10) Vehicle (n = 15) Vehicle (n = 5) Vehicle (n = 5) Sitagliptin (n = 5)
BW (g) 406.70 ± 6.83 388.10 ± 8.87 445.70 ± 8.16 354.40 ± 8.85aaa 380.00 ± 14.46
Glucose (mg/dl) 131.80 ± 1.20 512.00 ± 4.53aaa 133.40 ± 2.16 623.60 ± 7.30bb 520.44 ± 3.31ccc
HbA1c (%) 3.66 ± 0.15 9.96 ± 0.86aaa 3.76 ± 0.26 10.68 ± 0.75 8.68 ± 0.37ccc
Insulin (mU/ml) 14.82 ± 3.90 11.62 ± 1.15aaa 15.13 ± 3.34 7.16 ± 1.14bbb 11.19 ± 1.73ccc
HOMA-Beta (%) 77.70 ± 2.28 9.33 ± 0.83aaa 77.52 ± 1.10 4.60 ± 0.16bbb 8.82 ± 0.32ccc
TGs (mg/dl) 111.60 ± 8.33 366.00 ± 5.92aaa 158.40 ± 6.80 409.80 ± 8.04bb 255.60 ± 3.70ccc
  1. Values are means ± SEM of n rats. Comparisons between groups: aaa = p < 0.001 between diabetic versus control groups (20 or 26 weeks); bb and bbb = p < 0.01 and p < 0.001, respectively, within the diabetic group (26 versus 20 weeks); ccc = p < 0.001 between diabetic sitagliptin-treated versus diabetic untreated groups (at 26 weeks).